Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+50.0%
|
-
|
|
Mar 06
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,712
+3.6%
|
-
|
|
Mar 06
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+23.47%
|
-
|
|
Feb 27
2024
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
20,000
-42.22%
|
$1,440,000
$72.92 P/Share
|
|
Feb 27
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+40.31%
|
$360,000
$18.56 P/Share
|
|
Feb 26
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
13,337
-77.96%
|
$920,253
$69.43 P/Share
|
|
Feb 26
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,882
+50.0%
|
$211,752
$36.89 P/Share
|
|
Feb 26
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,907
-66.21%
|
$545,583
$69.4 P/Share
|
|
Feb 26
2024
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
26,328
-14.69%
|
$1,790,304
$68.83 P/Share
|
|
Feb 26
2024
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
36,757
+24.57%
|
$1,801,093
$49.47 P/Share
|
|
Feb 26
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,907
-5.65%
|
$545,583
$69.87 P/Share
|
|
Feb 26
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,112
-11.31%
|
$287,840
$70.19 P/Share
|
|
Feb 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,590
-0.71%
|
$1,558,710
$69.32 P/Share
|
|
Feb 23
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,455
+50.0%
|
-
|
|
Feb 23
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+50.0%
|
-
|
|
Feb 23
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+17.37%
|
-
|
|
Feb 23
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+36.76%
|
-
|
|
Feb 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,590
+2.06%
|
-
|
|
Feb 02
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
33,885
-1.58%
|
$2,270,295
$67.06 P/Share
|
|
Feb 02
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,860
-96.99%
|
$782,760
$66.77 P/Share
|
|
Feb 02
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
11,183
-99.17%
|
$738,078
$66.98 P/Share
|
|
Feb 02
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,860
-15.39%
|
$794,620
$67.08 P/Share
|
|
Feb 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,167
-29.94%
|
$413,189
$67.09 P/Share
|
|
Feb 01
2024
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,885
+3.03%
|
-
|
|
Feb 01
2024
|
Michael Halstead EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+50.0%
|
-
|
|
Feb 01
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,183
+50.0%
|
-
|
|
Feb 01
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+22.2%
|
-
|
|
Feb 01
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+50.0%
|
-
|
|
Jan 18
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
67,917
-3.04%
|
$4,414,605
$65.72 P/Share
|
|
Jan 18
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
67,917
+5.73%
|
$1,086,672
$16.86 P/Share
|
|
Jan 17
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
48,084
-2.21%
|
$3,173,544
$66.33 P/Share
|
|
Jan 17
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,084
+4.19%
|
$769,344
$16.86 P/Share
|
|
Jan 16
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
75,361
-2.25%
|
$5,049,187
$67.13 P/Share
|
|
Jan 16
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,361
+6.27%
|
$1,205,776
$16.86 P/Share
|
|
Jan 11
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-77.21%
|
$3,350,000
$67.07 P/Share
|
|
Jan 11
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+28.6%
|
$900,000
$18.34 P/Share
|
|
Jan 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
62,282
-83.73%
|
$4,359,740
$70.99 P/Share
|
|
Jan 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,282
+50.0%
|
$1,183,358
$19.87 P/Share
|
|
Dec 31
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
251
+0.32%
|
$17,821
$71.62 P/Share
|
|
Dec 31
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
76
+0.78%
|
$5,396
$71.62 P/Share
|
|
Dec 13
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,262
-100.0%
|
$1,382,030
$65.0 P/Share
|
|
Nov 13
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-58.93%
|
$2,650,000
$53.69 P/Share
|
|
Nov 13
2023
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.53%
|
$700,000
$14.1 P/Share
|
|
Nov 06
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
42,393
-35.8%
|
$2,331,615
$55.5 P/Share
|
|
Nov 06
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,754
+27.07%
|
$615,342
$23.94 P/Share
|
|
Sep 30
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
105
+1.09%
|
$5,460
$52.09 P/Share
|
|
Sep 30
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
345
+0.43%
|
$17,940
$52.09 P/Share
|
|
Sep 19
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
44,413
-4.06%
|
$2,398,302
$54.17 P/Share
|
|
Sep 18
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
55,587
-2.45%
|
$2,946,111
$53.75 P/Share
|
|
Aug 07
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
55,300
-54.95%
|
$3,207,400
$58.79 P/Share
|